VPTDF (VentriPoint Diagnostics) Operating Income: $-2.45 Mil (TTM As of Dec. 2025)

What is VentriPoint Diagnostics Operating Income?

VentriPoint Diagnostics VPTDF -4.66% 8 Operating Income is $-2.45 Mil as of Dec. 2025. GuruFocus rates VPTDF with a GF Score™ of 8/100. The stock has 4 warning signs investors should review.

VentriPoint Diagnostics's Operating Income for the three months ended in Dec. 2025 was $-0.54 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.45 Mil.

Warning Sign:

VentriPoint Diagnostics Ltd has never been profitable in the past 3 years. It lost money every year.

Operating Margin % is calculated as Operating Income divided by its Revenue. VentriPoint Diagnostics's Operating Income for the three months ended in Dec. 2025 was $-0.54 Mil. VentriPoint Diagnostics's Revenue for the three months ended in Dec. 2025 was $0.00 Mil. Therefore, VentriPoint Diagnostics's Operating Margin % for the quarter that ended in Dec. 2025 was -17,866.67%.

VentriPoint Diagnostics's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. VentriPoint Diagnostics's annualized ROC % for the quarter that ended in Dec. 2025 was -118.35%. VentriPoint Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -242.55%.

VentriPoint Diagnostics (OTCPK:VPTDF) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

VentriPoint Diagnostics's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-2.144 * ( 1 - 0% )	/	( (1.713	+	1.91)	/ 2 )
=	-2.144	/	1.8115
=	-118.35 %

where

	Invested Capital		(Q: Sep. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.273	-	1.925	-	( 0.049	-	max(0, 3.538	-	0.173	+	0.049	))
=	1.713

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.342	-	1.42	-	( 0.04	-	max(0, 3.242	-	0.254	+	0.04	))
=	1.91

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

VentriPoint Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2025		Q: Dec. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.228	/	( ( (0.1 + max(-1.892, 0))	+	(0.088 + max(-1.315, 0)) )	/	2 )
=	-0.228	/	( ( 0.1	+	0.088 )	/	2 )
=	-0.228	/	0.094
=	-242.55 %

where Working Capital is:

	Working Capital		(Q: Sep. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.016	+	0	+	0.034)	-	(1.925	+	0.017	+	0)
=	-1.892

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.118)	-	(1.42	+	0.013	+	0)
=	-1.315

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. Operating Income is also linked to Operating Margin %:

VentriPoint Diagnostics's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as:

Operating Margin %	=	Operating Income (Q: Dec. 2025 )	/	Revenue (Q: Dec. 2025 )
	=	-0.536	/	0.003
	=	-17,866.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

VentriPoint Diagnostics Operating Income Related Terms

VentriPoint Diagnostics Operating Income Historical Data

* Premium members only.

The historical data trend for VentriPoint Diagnostics's Operating Income can be seen below:

VentriPoint Diagnostics Operating Income Chart

VentriPoint Diagnostics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Operating Income

Get a 7-Day Free Trial

-2.84

-3.54

-3.63

-3.37

-2.47

VentriPoint Diagnostics Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
Operating Income	Get a 7-Day Free Trial															-0.74	-0.59	-0.86	-0.47	-0.54

8GF Score

VentriPoint Diagnostics Ltd VPTDF

Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

VentriPoint Diagnostics Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.45 Mil.

Frequently Asked Questions Learn more about Operating Income →

What does a Operating Income of $-2.45 Mil mean?

VentriPoint Diagnostics (VPTDF) has a Operating Income of $-2.45 Mil as of Dec. 2025. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on VentriPoint Diagnostics and its competitors.

Is VentriPoint Diagnostics' Operating Income too high?

VentriPoint Diagnostics' current Operating Income is $-2.45 Mil. Overall, VentriPoint Diagnostics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.

How does VentriPoint Diagnostics' Operating Income compare to ABT and SYK?

VentriPoint Diagnostics' Operating Income of $-2.45 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Operating Income for a Medical Devices & Instruments company?

A good Operating Income depends on the Medical Devices & Instruments industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Operating Income mean?

A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on VentriPoint Diagnostics and its competitors. VentriPoint Diagnostics's current Operating Income is $-2.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is VentriPoint Diagnostics stock overvalued right now?

VentriPoint Diagnostics (VPTDF) has a current Operating Income of $-2.45 Mil. The current Operating Income is $-2.45 Mil. VentriPoint Diagnostics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Operating Income calculated?

Operating Income is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current Operating Income is $-2.45 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VentriPoint Diagnostics Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies TSXV:ASG TSXV:MDX TSXV:CNVI TSXV:VVTM TSXV:PAIN TSXV:FREQ TSXV:CHER XCNQ:QAI TSXV:NGMD TSXV:THRM ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Other Exchanges VPT:Canada

Address 18 Hook Avenue, Unit 101, Toronto, ON, CAN, M6P 1T4

Website https://www.ventripoint.com

VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.

8GF Score

Get the complete analysis for VPTDF

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08

Price

View VPTDF Analysis

See Operating Income data for all stocks →